The price of entrectinib entering medical insurance

Entrectinib is an oral, small-molecule targeted drug used to treat certain types of cancer, including non-small cell lung cancer (NSCLC) and certain neuronal tumors. The drug is a multi-target inhibitor of ROS1, ALK and NTRK proteins, which play important roles in some cancers.

Entrectinib is now on the market in China and has been successfully included in the medical insurance system. Domestic patients can purchase it directly. However, its price is quite expensive, with a cost of about 20,000 yuan. For detailed information on specific prices and medical insurance reimbursement, please consult your local hospital pharmacy for accurate answers. In comparison, the price of entrectinib generic drugs in foreign markets is more affordable, especially the generic drugs in Laos, which cost only about one to two thousand yuan, and their drug ingredients are basically the same as the original drugs. Therefore, patients can reasonably choose purchasing channels based on their own financial status and treatment needs.

Enrectinib is a major advance in cancer treatment, especially for those with cancers that have specific genetic mutations. Its mechanism of action is to inhibit the growth and spread of cancer cells by blocking specific signaling pathways in cancer cells.

For patients with ALK and ROS1 mutationsNSCLC, entrectinib provides a new treatment option. These mutations are one of the more common types of lung cancer, and traditional chemotherapy and other treatments may be ineffective or have limited effectiveness in these patients. The use of entrectinib has resulted in better survival and quality of life for these patients.

In addition, entrectinib has also shown good efficacy in tumors that are positive forNTRK gene fusions, including a variety of cancer types, such as infantile fibrosarcoma and adult solid tumors. The drug is considered a promising treatment option in these patients and is often used along with personalized genetic testing to determine whether a patient is a candidate for treatment with the drug.